BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

319 related articles for article (PubMed ID: 21310730)

  • 1. Regimen selection for first-line FOLFIRI and FOLFOX based on UGT1A1 genotype and physical background is feasible in Japanese patients with advanced colorectal cancer.
    Ishida H; Fujita K; Akiyama Y; Sunakawa Y; Yamashita K; Mizuno K; Miwa K; Kawara K; Ichikawa W; Ando Y; Saji S; Sasaki Y
    Jpn J Clin Oncol; 2011 May; 41(5):617-23. PubMed ID: 21310730
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bevacizumab plus FOLFIRI or FOLFOX as third-line or later treatment in patients with metastatic colorectal cancer after failure of 5-fluorouracil, irinotecan, and oxaliplatin: a retrospective analysis.
    Kang BW; Kim TW; Lee JL; Ryu MH; Chang HM; Yu CS; Kim JC; Kim JH; Kang YK; Lee JS
    Med Oncol; 2009; 26(1):32-7. PubMed ID: 18498064
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Safety and efficacy of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) in Chinese patients with advanced colorectal cancer].
    Song Y; Li WW; Huang J
    Zhonghua Zhong Liu Za Zhi; 2017 May; 39(5):380-383. PubMed ID: 28535657
    [No Abstract]   [Full Text] [Related]  

  • 4. Efficacy and safety of an irinotecan plus bolus 5-fluorouracil and L-leucovorin regimen for metastatic colorectal cancer in Japanese patients: experience in a single institution in Japan.
    Yoshino T; Boku N; Onozawa Y; Hironaka S; Fukutomi A; Yamaguchi Y; Hasuike N; Yamazaki K; Machida N; Ono H
    Jpn J Clin Oncol; 2007 Sep; 37(9):686-91. PubMed ID: 17720736
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and tolerability of oxaliplatin plus irinotecan 5-fluouracil and leucovorin regimen in advanced stage colorectal cancer patients pretreated with irinotecan 5-fluouracil and leucovorin.
    Stathopoulos GP; Rigatos SK; Stathopoulos JG; Xynotroulas JP; Dimou E
    Am J Clin Oncol; 2005 Dec; 28(6):565-9. PubMed ID: 16317265
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comprehensive analysis of excision repair complementation group 1, glutathione S-transferase, thymidylate synthase and uridine diphosphate glucuronosyl transferase 1A1 polymorphisms predictive for treatment outcome in patients with advanced gastric cancer treated with FOLFOX or FOLFIRI.
    Seo BG; Kwon HC; Oh SY; Lee S; Kim SG; Kim SH; Han H; Kim HJ
    Oncol Rep; 2009 Jul; 22(1):127-36. PubMed ID: 19513514
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Multicenter Clinical Phase II Study of FOLFOXIRI Plus Bevacizumab as First-line Therapy in Patients With Metastatic Colorectal Cancer: QUATTRO Study.
    Oki E; Kato T; Bando H; Yoshino T; Muro K; Taniguchi H; Kagawa Y; Yamazaki K; Yamaguchi T; Tsuji A; Iwamoto S; Nakayama G; Emi Y; Touyama T; Nakamura M; Kotaka M; Sakisaka H; Yamanaka T; Kanazawa A
    Clin Colorectal Cancer; 2018 Jun; 17(2):147-155. PubMed ID: 29530335
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and Safety of FOLFIRI Regimen in Elderly Versus Nonelderly Patients with Metastatic Colorectal or Gastric Cancer.
    Kim JW; Lee KW; Kim KP; Lee JH; Hong YS; Kim JE; Kim SY; Park SR; Nam BH; Cho SH; Chung IJ; Park YS; Oh HS; Lee MA; Kang HJ; Park YI; Song EK; Han HS; Lee KT; Shin DB; Kang JH; Zang DY; Kim JH; Kim TW
    Oncologist; 2017 Mar; 22(3):293-303. PubMed ID: 28209749
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dose-finding study of weekly 24-h continuous infusion of 5-fluorouracil associated with alternating oxaliplatin or irinotecan in advanced colorectal cancer patients.
    Cals L; Rixe O; François E; Favre R; Merad L; Deplanque G; Laadem A; Juin P; Bereder JM; Bernardini D; Herait P
    Ann Oncol; 2004 Jul; 15(7):1018-24. PubMed ID: 15205194
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer.
    Goldberg RM; Sargent DJ; Morton RF; Fuchs CS; Ramanathan RK; Williamson SK; Findlay BP; Pitot HC; Alberts SR
    J Clin Oncol; 2004 Jan; 22(1):23-30. PubMed ID: 14665611
    [TBL] [Abstract][Full Text] [Related]  

  • 11. UGT1A1*6, 1A7*3, and 1A9*22 genotypes predict severe neutropenia in FOLFIRI-treated metastatic colorectal cancer in two prospective studies in Japan.
    Hazama S; Mishima H; Tsunedomi R; Okuyama Y; Kato T; Takahashi K; Nozawa H; Ando H; Kobayashi M; Takemoto H; Nagata N; Kanekiyo S; Inoue Y; Hamamoto Y; Fujita Y; Hinoda Y; Okayama N; Oba K; Sakamoto J; Oka M
    Cancer Sci; 2013 Dec; 104(12):1662-9. PubMed ID: 24033692
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 5-Fluorouracil/leucovorin combined with irinotecan and oxaliplatin (FOLFIRINOX) as second-line chemotherapy in patients with advanced pancreatic cancer who have progressed on gemcitabine-based therapy.
    Lee MG; Lee SH; Lee SJ; Lee YS; Hwang JH; Ryu JK; Kim YT; Kim DU; Woo SM
    Chemotherapy; 2013; 59(4):273-9. PubMed ID: 24457620
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fluorouracil, leucovorin, and irinotecan plus either sunitinib or placebo in metastatic colorectal cancer: a randomized, phase III trial.
    Carrato A; Swieboda-Sadlej A; Staszewska-Skurczynska M; Lim R; Roman L; Shparyk Y; Bondarenko I; Jonker DJ; Sun Y; De la Cruz JA; Williams JA; Korytowsky B; Christensen JG; Lin X; Tursi JM; Lechuga MJ; Van Cutsem E
    J Clin Oncol; 2013 Apr; 31(10):1341-7. PubMed ID: 23358972
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I/II study of FOLFIRI in Japanese patients with advanced colorectal cancer.
    Yamashita K; Nagashima F; Fujita K; Yamamoto W; Endo H; Miya T; Narabayashi M; Kawara K; Akiyama Y; Ando Y; Ando M; Sasaki Y
    Jpn J Clin Oncol; 2011 Feb; 41(2):204-9. PubMed ID: 20965940
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase I study of infusional 5-fluorouracil, leucovorin, oxaliplatin and irinotecan in Japanese patients with advanced colorectal cancer who harbor UGT1A1*1/*1,*1/*6 or *1/*28.
    Sunakawa Y; Fujita K; Ichikawa W; Ishida H; Yamashita K; Araki K; Miwa K; Kawara K; Akiyama Y; Yamamoto W; Nagashima F; Saji S; Sasaki Y
    Oncology; 2012; 82(4):242-8. PubMed ID: 22508373
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest.
    Falcone A; Ricci S; Brunetti I; Pfanner E; Allegrini G; Barbara C; Crinò L; Benedetti G; Evangelista W; Fanchini L; Cortesi E; Picone V; Vitello S; Chiara S; Granetto C; Porcile G; Fioretto L; Orlandini C; Andreuccetti M; Masi G;
    J Clin Oncol; 2007 May; 25(13):1670-6. PubMed ID: 17470860
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Irinotecan plus S-1 (IRIS) versus fluorouracil and folinic acid plus irinotecan (FOLFIRI) as second-line chemotherapy for metastatic colorectal cancer: a randomised phase 2/3 non-inferiority study (FIRIS study).
    Muro K; Boku N; Shimada Y; Tsuji A; Sameshima S; Baba H; Satoh T; Denda T; Ina K; Nishina T; Yamaguchi K; Takiuchi H; Esaki T; Tokunaga S; Kuwano H; Komatsu Y; Watanabe M; Hyodo I; Morita S; Sugihara K
    Lancet Oncol; 2010 Sep; 11(9):853-60. PubMed ID: 20708966
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Axitinib or bevacizumab plus FOLFIRI or modified FOLFOX-6 after failure of first-line therapy for metastatic colorectal cancer: a randomized phase II study.
    Bendell JC; Tournigand C; Swieboda-Sadlej A; Barone C; Wainberg ZA; Kim JG; Pericay C; Pastorelli D; Tarazi J; Rosbrook B; Bloom J; Ricart AD; Kim S; Sobrero AF
    Clin Colorectal Cancer; 2013 Dec; 12(4):239-47. PubMed ID: 24188685
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and toxicity of fluorouracil, leucovorin plus oxaliplatin (FOLFOX4 and modified FOLFOX6) followed by fluorouracil, leucovorin plus irinotecan(FOLFIRI)for advanced or metastatic colorectal cancer--case studies.
    Ohtani H; Arimoto Y; Nishio K; Kanamiya Y; Oba H; Adachi K; Shintani M; Nakamura R; Yui S
    Gan To Kagaku Ryoho; 2008 Oct; 35(10):1769-74. PubMed ID: 18931586
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics, safety, and efficacy of FOLFIRI plus bevacizumab in Japanese colorectal cancer patients with UGT1A1 gene polymorphisms.
    Suenaga M; Fuse N; Yamaguchi T; Yamanaka Y; Motomura S; Matsumoto H; Hamamoto Y; Mizunuma N; Doi T; Hatake K; Iwasaki J; Ohtsu A
    J Clin Pharmacol; 2014 May; 54(5):495-502. PubMed ID: 24382596
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.